Gilead Buys Out Rights To Cancer Therapy From Jounce For $67 Million

Gilead Buys Out Rights To Cancer Therapy From Jounce For $67 Million

(Reuters) – Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday. The amended licensing deal will bolster Jounce’s cash resources in a challenging market for biotech companies. Shares of Jounce more than doubled to $1.68, while Gilead’s shares fell…

Read More
Japan Asks Its Insurers To Retain Marine War Cover For LNG Shippers In Russian Waters

Japan Asks Its Insurers To Retain Marine War Cover For LNG Shippers In Russian Waters

TOKYO (Reuters) – The Japanese government has asked insurers to take on additional risks to continue providing marine war insurance for liquefied natural gas (LNG) shippers in Russian waters, a senior official at the industry ministry said. The Financial Services Agency and Agency for Natural Resources and Energy made the rare request in a joint…

Read More